太阳成集团tyc234cc - 歡迎您!

Company News

BRL Medicinewas awarded "China future healthcare ranking 2020-2021—Top 100"

2021-04-20

Recently, "the 5th future healthcare VB100 conference " was held in Wujiang, Suzhou with the theme of "Calculation of life". The organizer, Artery.com, released the list of "the 5th future healthcare VB100 conference, and Bioraylab was awarded China future healthcare ranking 2020-2021—Top 100 biomedicine companies by virtue of its outstanding industry influence, continuous innovation and high growth.

Award Ceremony Scene


BRL Medicine helps to develop the field of oncology and genetic diseases


Thalassemia is one of the most widespread monogenic genetic diseases in the world and affects the largest number of people, with beta and alpha thalassemia being the most common. Allogeneic hematopoietic stem cell transplantation (HSC) is currently the only method to cure beta thalassemia, but it is expensive and extremely difficult to match. Gene therapy has brought a new light to these patients with the potential of "once-treatment-for-life cure". At present, two patients with severe beta-hemoglobin who were treated with gene therapy by BRL Medicine and Xiangya Hospital Central South University have been cured and discharged from the hospital and have been free from blood transfusion dependence for more than 10 months, and their total hemoglobin has reached the normal range. It is worth mentioning that this is the first gene editing technology to treat thalassemia in Asia and the first successful case of treating β0/β0 severe thalassemia by CRISPR gene editing technology in the world. This event also represents a breakthrough in clinical research of gene editing therapy in China.


Non-Hodgkin's lymphoma is a hematologic malignancy that originates in lymphoid tissue and accounts for 80-90% of all lymphomas. Although patients experience disease remission after initial treatment, relapse often occurs thereafter. Although CART products have been approved for the clinical treatment of relapsed refractory non-Hodgkin's lymphoma, the overall efficacy is still limited, and some studies suggest that inhibition of PD1 pathway may bring better clinical results. Bioraylab utilizes its proprietary Quikin CART® platform technology to prepare the obtained CAR-T products in one step without the use of viral vectors. Several patients rapidly achieved complete remission after treatment with BRL Medicine's non-viral PD1 targeted integration CD19-CART cells. This is the world's first CAR-T treatment using gene editing technology to achieve targeted integration at the PD1 locus, and the first clinical trial of non-viral targeted integration of CAR-T cells for lymphoma in the world.


Empowering the industry and exploring new models in the gene/cell therapy industry


Since its establishment, BRL Medicine has been committed to exploring new models in the gene/cell therapy industry. Early on, it relied on its own R&D center to establish the "Shanghai Research Center for Gene Editing and Cell Therapy" with East China Normal University to rapidly promote the deep integration of industry, academia and research. In the past 5 years, 120 domestic and foreign patents have been generated, forming a global patent layout, and many academic papers have been published in international famous academic journals such as Nature Biotechnology, Nature Medicine, Nature Cell Biology, Cell Research, etc. Especially, the successive breakthroughs in the development of single-base editing tools have provided new opportunities for basic research and treatment of genetic diseases such as β-thalassemia. The breakthroughs in the development of single-base editing tools have provided new directions and tools for basic research and treatment of genetic diseases such as β-thalassemia.


BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T cell Platforms, and has a 6000 square meter GMP pilot plant and an operating team of nearly 200 people, which strongly guarantees the rapid transformation and application of innovative research.

Back to top